更新形淋巴瘤激酶阳性非小细胞肺癌治疗的进展
Beatriz E Jimenez Munarriz1, Sam Khan1,2, Yuchen Li1,3,4
1Medical Oncology Department, University Health Network-Princess Margaret Cancer Center, Toronto, Ontario, Canada.
Cancer
|April 2, 2025
概括
无细胞淋巴瘤激酶 (ALK) 的重组影响了晚期非小细胞肺癌 (NSCLC) 的治疗. ALK氨酸激酶抑制剂 (TKIs) 改善了结果,本次审查涵盖了当前的选择,疗效和未来的方向.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 肺癌仍然是全球癌症死亡的主要原因.
- 向治疗和免疫检查点抑制剂显著改善了患者的生存率和生活质量.
- 在约5%的晚期非小细胞肺癌 (NSCLC) 病例中发现了亚纳普拉斯性淋巴瘤激酶 (ALK) 的重组.
研究的目的:
- 审查ALK重组NSCLC的当前治疗选择.
- 讨论ALK氨酸激酶抑制剂 (TKI) 的疗效,安全性和耐药性机制.
- 在ALK向治疗领域探索有前途的新疗法.
主要方法:
- 关于ALK抑制剂的现有数据的文献综述.
- 对治疗疗效和安全性概况的分析.
- 检查ALK耐药机制和新兴疗法.
主要成果:
- ALK氨酸激酶抑制剂 (TKIs) 已经改变了ALK重组NSCLC的治疗环境.
- 虽然对后一代抑制剂的对比试验有限,但现有的数据显示了不同的疗效和安全性.
- 了解耐药机制对于优化治疗策略至关重要.
结论:
- 阿尔克抑制剂代表了NSCLC个性化医学的重大进步.
- 对新型抑制剂和组合疗法的持续研究对于克服耐药性和改善患者治疗结果至关重要.
- 本综述提供了对NSCLC中ALK向治疗的当前状态和未来前景的全面概述.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.5K
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
1.6K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy
432
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
432
